FDA Grants Fast Track Designation for TRE-515 in Combination with KRAS G12C Inhibitors for the Treatment of NSCLC October 6, 2026
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million October 6, 2026
First Patient Enrolled in Global Ph 3 Trial of Cadonilimab vs Nivolumab in 1L Gastric Cancer October 6, 2026
Giredestrant combination significantly improved PFS in ER-positive advanced breast cancer in Ph 3 evERA; data published in The NEJM October 6, 2026
AstraZeneca, Daiichi Sankyo, and Summit Therapeutics to evaluate Datroway + ivonescimab combo across multiple tumour types October 6, 2026
Epcoritamab + R-CHOP combo Demonstrates Significant PFS Improvement versus R-CHOP in 1L DLBCL Patients October 6, 2026
NDA Submission Initiated for Zipalertinib + Chemo in 1L EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program October 6, 2026
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences October 6, 2026
United Immunity Announces Master Clinical Supply Agreement with Roche to Evaluate UI-102 + Anti–PD-L1 Therapy in Advanced Solid Tumors October 6, 2026
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma October 6, 2026
Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs October 6, 2026
First patient dosed with LNK001 in Ph 1 study in patients with advanced or metastatic clear cell RCC October 6, 2026
Second Patient treated in the Fifth Cohort of Ovarian Cancer FSHR-targeted CAR-T Clinical Trial October 6, 2026
Results from VIRAGE Ph 2b Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine October 6, 2026
Positive topline results from Ph 3 AZTOUND trial of oral azacitidine and cedazuridine (ASTX030) in MDS and CMML patients announced October 6, 2026
RD140 achieved ~89% ORR & MRD negativity rate in heavily pretreated, high-risk RRMM or plasma cell leukemia patients October 6, 2026
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC) October 6, 2026
Rinatabart Sesutecan (Rina-S®) Ph 2 RAINFOL™-01 Results Demonstrate Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer October 6, 2026
